Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 142

Sort by

Sort Order Select

Journal Articles

Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial

Blood (2025) 146 (Supplement 1): 237.

https://doi.org/10.1182/blood-2025-237

Published: 2025

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Ross Baker, Chih-Cheng Chen, Tsai-Yun Chen, Stanley Cheung, Hui-Hua Hsiao, Jae Hoon Lee, Ji Yun Lee, Sung-Eun Lee, Won Sik Lee, Lucia Masarova, Peter Tan, Shuhying Tan, Pankit Vachhani, Anne Marie Watson, Shang-Ju Wu, Jana Baskar, Joanna Leadbetter, Wolfgang Jarolimek

Blood (2025) 146 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2025-2027

Published: 2025

Journal Articles

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Warren Fiskus, Christopher Mill, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Arnav Gupta, Hanxi Hou, Taghi Manshouri, Jayastu Senapati, Sanam Loghavi, Andrew Dunbar, Claes Wahlestedt, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2025-5053

Published: 2025

Journal Articles

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor, Zachary Zaroogian, Shishir Waghray, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Taghi Manshouri, Kapil Bhalla, Claes Wahlestedt, Ross Levine, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2025-3759

Published: 2025

Journal Articles

Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis

Wei Xiao, Annie Hoai Nguyen, Ivo Veletic, Taghi Manshouri, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3758.

https://doi.org/10.1182/blood-2025-3758

Published: 2025

Journal Articles

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Caitlin Rausch, Gautam Borthakur, Fadi Haddad, Kelly Chien, Danielle Hammond, Guillermo Montalban-Bravo, Naveen Pemmaraju, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Jan Burger, Nitin Jain, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2025-3457

Published: 2025

Journal Articles

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Aaron Gerds, Lindsay Rein, Nicole Engel-Nitz, Michael Marrone, Jeffrey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg, Yong Zhu, Lucia Masarova

Blood (2025) 146 (Supplement 1): 5576.

https://doi.org/10.1182/blood-2025-5576

Published: 2025

Journal Articles

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Ivo Veletic, Taghi Manshouri, Christopher Pacheco, Christopher Ly, C. Cameron Yin, Jared Burks, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 5542.

https://doi.org/10.1182/blood-2025-5542

Published: 2025

Journal Articles

Dose intensive regimen of CK0804 tregs in myelofibrosis

Lucia Masarova, Mehrdad Abedi, Naveen Pemmaraju, Prithviraj Bose, Tapan Kadia, Jo Ishizawa, Guillermo Montalban-Bravo, Tara Sadeghi, Simrit Parmar, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5602.

https://doi.org/10.1182/blood-2025-5602

Published: 2025

Journal Articles

Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort

Annie Hoai Nguyen, Wei Xiao, Ivo Veletic, Taghi Manshouri, Julie Braish, Georgina El Hajjar, Ghayas Issa, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3813.

https://doi.org/10.1182/blood-2025-3813

Published: 2025

Journal Articles

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5228.

https://doi.org/10.1182/blood-2025-5228

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)

Farah Al Haj, Mina Abdelmalek, Jayastu Senapati, Guillermo Montalban-Bravo, Stefan Faderl, William D. Marrero, Nicholas Short, Naval Daver, Courtney DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Tapan Kadia, Farhad Ravandi, Yesid Alvarado Valero

Blood (2025) 146 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2025-1688

Published: 2025

Journal Articles

How I individualize selection of JAK inhibitors for patients with myelofibrosis

Lucia Masarova, Helen T. Chifotides

Blood (2025) 145 (16): 1724–1737.

https://doi.org/10.1182/blood.2023022415

Published: 2025

Includes: Supplemental data

Journal Articles

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Blood (2025) 145 (6): 612–624.

https://doi.org/10.1182/blood.2024026388

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Gautam Borthakur, Srdan Verstovsek, C. Cameron Yin, Keyur P. Patel, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2024-211674

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Dose intensive regimen of CK0804 tregs in myelofibrosis

Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)

How I individualize selection of JAK inhibitors for patients with myelofibrosis

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only